Benjamin A. Schiffman

Array ( [id] => 17314531 [patent_doc_number] => 20210403579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => MULTIVALENT REGULATORY T CELL MODULATORS [patent_app_type] => utility [patent_app_number] => 17/290129 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56604 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 1807 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272951 [patent_doc_number] => 20210379149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy [patent_app_type] => utility [patent_app_number] => 17/287862 [patent_app_country] => US [patent_app_date] => 2019-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26397 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837776 [patent_doc_number] => 20220275081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => BINDING MOLECULE SPECIFIC FOR LRIG-1 PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/286429 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837775 [patent_doc_number] => 20220275080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => BINDING MOLECULE SPECIFIC TO LRIG-1 PROTEIN, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/286424 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18285557 [patent_doc_number] => 20230101029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => METHODS OF USING IL-33 PROTEIN IN TREATING CANCERS [patent_app_type] => utility [patent_app_number] => 17/767952 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17080492 [patent_doc_number] => 20210275498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID FOR USE IN THERAPY OF SYMPTOMS RELATED TO EXPOSURE TO LETHAL RADIATION [patent_app_type] => utility [patent_app_number] => 17/279625 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414112 [patent_doc_number] => 20220049016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => Antibody for Specifically Binding to Lysyl-tRNA Synthetase N-Terminal Domain Exposed to Extracellular Membrane [patent_app_type] => utility [patent_app_number] => 17/276570 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399619 [patent_doc_number] => 20220041709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY-CONTAINING PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/276106 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 234 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19579890 [patent_doc_number] => 12145988 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-19 [patent_title] => Anti-TREM-2 agonist antibodies [patent_app_type] => utility [patent_app_number] => 17/275092 [patent_app_country] => US [patent_app_date] => 2019-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 22475 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19457697 [patent_doc_number] => 12098177 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cells [patent_app_type] => utility [patent_app_number] => 17/274127 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7921 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18271653 [patent_doc_number] => 20230092895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => TANDEM CD19 CAR-BASED COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/753320 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036774 [patent_doc_number] => 20210253732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => ANTIGEN-BINDING FRAGMENT AND/OR APTAMER FOR BINDING TO AN EXTRACELLULAR PART OF CD9 AND THERAPEUTIC USES [patent_app_type] => utility [patent_app_number] => 17/271690 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185454 [patent_doc_number] => 20210332339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => NOVEL NUCLEASE DOMAIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/271481 [patent_app_country] => US [patent_app_date] => 2019-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931763 [patent_doc_number] => 12304960 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Anti-CD137 antigen-binding molecule and utilization thereof [patent_app_type] => utility [patent_app_number] => 17/266024 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 76 [patent_figures_cnt] => 91 [patent_no_of_words] => 109427 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20634426 [patent_doc_number] => 12595293 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-07 [patent_title] => Anti-follicle stimulating hormone receptor antibodies [patent_app_type] => utility [patent_app_number] => 17/267331 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 20 [patent_no_of_words] => 14774 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17267331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868532 [patent_doc_number] => 20210161999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => COMPOSITIONS AND METHODS RELATED TO OVERCOMING INNATE IMMUNE BARRIERS TO CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/266993 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19897885 [patent_doc_number] => 12275791 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use [patent_app_type] => utility [patent_app_number] => 17/265876 [patent_app_country] => US [patent_app_date] => 2019-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 36 [patent_no_of_words] => 24927 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17265876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17141738 [patent_doc_number] => 20210309750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => Enhanced Delivery of Drugs and Other Compounds to the Brain and Other Tissues [patent_app_type] => utility [patent_app_number] => 17/265731 [patent_app_country] => US [patent_app_date] => 2019-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17265731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140232 [patent_doc_number] => 20210308243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => OPTIMIZED SYNTHETIC CONSENSUS IMMUNOGENIC COMPOSITIONS TARGETING CHONDROITIN SULFATE PROTEOGLYCAN 4 (CSPG4) [patent_app_type] => utility [patent_app_number] => 17/264545 [patent_app_country] => US [patent_app_date] => 2019-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17264545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17124487 [patent_doc_number] => 20210299255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => COMPOSITIONS OF FCRN ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/260318 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11442 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17260318 [rel_patent_id] =>[rel_patent_doc_number] =>)